IL2 and systemic lupus erythematosus: In a prospective open-label study of 50 patients with refractory SLE who received low-dose IL-2 for 3 to 5 days monthly and 0.5 mg rapamycin (oral) alternate days, significant improvement of SLE disease activity was noted up to 24 weeks, accompanied by a decrease of circulating Th17/Treg ratio [62].